米国の放射線皮膚炎市場規模、シェア、動向分析レポート：製品タイプ別、流通チャネル別、施設タイプ別、セグメント予測、2024年～2030年

米国の放射線皮膚炎市場の成長と動向：

Grand View Research社の最新レポートによると、米国の放射線皮膚炎市場規模は2030年までに4億8,107万米ドルに達し、2024年から2030年までのCAGRは5.5％で成長すると予測されています。

がんの有病率の増加、放射線治療技術の主な発展、放射線皮膚炎に対する新たな治療オプションの開発など、いくつかの重要な要因がこの成長に寄与しています。がんの負担増は市場成長を促進する重要な要因です。がんは世界的に主要な死因の一つであるため、効果的な放射線療法とそれに続く放射線皮膚炎の管理に対する需要が高まっています。乳がんや前立腺がんなど、放射線療法を必要とすることが多いがん種の発生率が高いことも、市場拡大を後押しすると予想されます。さらに、がんなどの慢性疾患にかかりやすい高齢人口の増加が、放射線皮膚炎治療の需要を押し上げています。

また、局所クリーム、ドレッシング剤、経口薬など、放射線皮膚炎に対する新たな治療オプションの開拓が市場範囲を拡大していることも、市場拡大に影響を与えています。これらの技術革新は、患者に症状管理の選択肢を提供し、放射線皮膚炎の重症例に関連するQOLの改善とヘルスケアコストの削減につながる可能性があるが、従来の放射線皮膚炎管理ソリューションの需要を減少させる可能性もあります。例えば、2024年4月、Molnlycke社は、著名な創傷洗浄メーカーであるP.G.F. Industry Solutions GmbH社を買収することで合意したと発表しました。この買収により、同社は創傷ケアの世界的リーダーとしての地位を強化することが期待されます。

さらに、放射性皮膚炎を管理することの重要性に対する医療従事者や患者の認識や教育が高まっていることも成長に影響しています。このような認識により、放射線皮膚炎の重症度を最小限に抑え、患者の転帰を改善する上で極めて重要な予防対策と早期介入が重視されるようになっています。効果的な放射線皮膚炎治療を開発・促進するためのヘルスケア提供者、研究開発者、製薬企業間の協力関係は、市場拡大をさらに後押ししています。このように、がんの有病率の増加、放射線治療と治療オプションの進歩、放射線皮膚炎管理に関する認識と教育の高まりが複合的に影響し、業界の成長に寄与すると予想されます。

米国の放射線皮膚炎市場レポート・ハイライト

• 2023年の売上シェアは、外用剤が75.68%を占めました。このシェアは、放射線皮膚炎の症状管理に外用製品が広く使用されていることに起因しています。
• クリームや軟膏を含む外用治療は、患部に直接塗布することができ、即座に緩和をもたらし、全身的な副作用のリスクを軽減します。
• 2023年には、小売薬局セグメントが最大の売上シェアを占めました。この成長は、アクセスのしやすさと利便性に起因しています。小売薬局は、放射線皮膚炎などの症状に対して市販の治療を求める多くの患者にとって、主要な接点となっています。
• 独立放射線治療センターセグメントは、2023年に最大の収益シェアを占めました。これは、先進的な放射線治療、放射線被曝の低減、腫瘍ターゲットの精度の向上に重点を置いているためです。さらに、これらのセンターは、より個別化されたアプローチをとることが多く、患者の満足度やリピート率の向上につながる可能性があります。
• 市場プレーヤーは、さまざまな地域にわたって製品のリーチと可用性を高めるために、さまざまな戦略的イニシアチブをとっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の放射線皮膚炎市場の変数、動向、範囲

• 市場系統の見通し
  • 関連/付随市場の見通し
• 米国におけるさまざまながんの罹患率
• 2024年の米国における各種がんの発生率と死亡率
• 2024年の米国におけるがん発症率の予測（州別）
• 2024年に米国で放射線療法を選択し放射線皮膚炎を患う患者の数
• がんの種類による放射線皮膚炎の程度
• 臨床パラメータを用いたがんによる放射線皮膚炎の特徴づけ
• 放射線治療施設の種類（米国における各種がん）
• 放射線皮膚炎治療の平均製品コスト
• 製品市場の機会
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 米国の放射線皮膚炎市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国の放射線皮膚炎市場：製品の推定・動向分析

• 米国の放射線皮膚炎市場：製品ダッシュボード
• 米国の放射線皮膚炎市場：製品変動分析
• 米国の放射線皮膚炎市場規模と予測および動向分析、製品別、2018～2030年
• 外用
• 被覆材

第5章 米国の放射線皮膚炎市場：流通チャネルの推定・動向分析

• 米国の放射線皮膚炎市場：流通チャネルダッシュボード
• 米国の放射線皮膚炎市場：流通チャネル変動分析
• 米国の放射線皮膚炎市場規模と予測および動向分析、流通チャネル別、2018～2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第6章 米国の放射線皮膚炎市場：施設タイプの推定・動向分析

• 米国の放射線皮膚炎市場：施設タイプダッシュボード
• 米国の放射線皮膚炎市場：施設タイプの変動分析
• 米国の放射線皮膚炎市場規模と予測および動向分析、施設タイプ別、2018～2030年
• 病院併設放射線治療センター
• 独立放射線治療センター

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターとチャネルパートナーのリスト
  • Stratpharma AG
  • Smith &Nephew plc
  • Molnlycke Health Care AB
  • Derma Sciences Inc
  • Convatec Inc
  • 3M Company
  • Alliqua BioMedical
  • BMG Pharma spA

List of Tables

• Table 1 List of secondary sources
• Table 2 5-year prevalence of different cancer types in the U.S.
• Table 3 Incidence and mortality rates of different cancer types in the U.S. in 2024
• Table 4 Average product cost for radiodermatitis treatment in the U.S.
• Table 5 U.S. radiodermatitis market revenue estimates and forecast, by product, 2018 - 2030 (USD Million)
• Table 6 U.S. radiodermatitis market revenue estimates and forecast, by facility type, 2018 - 2030 (USD Million)
• Table 7 U.S. radiodermatitis market analysis revenue estimates and forecast, by distribution channel, 2018 - 2030 (USD Million)
• Table 8 Key companies undergoing product launches.
• Table 9 Key companies undergoing partnerships & collaborations
• Table 10 Key companies undergoing initiating mergers/acquisitions.
• Table 11 Key companies undergoing other strategies.

List of Figures

• Fig. 1 U.S. radiodermatitis market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Epidemiology-based market analysis
• Fig. 8 QFD modelling for market share assessment
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (Product and distribution channel)
• Fig. 11 Segment snapshot (Facility type)
• Fig. 12 Competitive landscape snapshot
• Fig. 13 5-year prevalence of cancer in the U.S.
• Fig. 14 Leading cancer types (incidence and mortality)
• Fig. 15 Top 10 U.S. states contributing to highest cancer cases in 2024
• Fig. 16 Top 10 U.S. states contributing to breast, colon, rectum, lung and bronchus, and prostate cancer cases in 2024
• Fig. 17 Estimated patients undergoing radiation therapy and suffering from radiodermatitis in the U.S. for selected cancer types in 2024
• Fig. 18 Stage wise distribution of cancer patients receiving radiation therapies-I
• Fig. 19 Stage wise distribution of cancer patients receiving radiation therapies-II
• Fig. 20 Grade of radiodermatitis for different cancer types
• Fig. 21 Characterization of radiodermatitis for cancer using clinical parameters
• Fig. 22 Facility types for radiation therapy in the U.S.
• Fig. 23 Market opportunity in the U.S.
• Fig. 24 Market potential for topical and dressing products for radiodermatitis treatment in the U.S.
• Fig. 26 U.S. Radiodermatitis Market: Product dashboard
• Fig. 27 U.S. radiodermatitis market: Product movement analysis
• Fig. 28 U.S. Radiodermatitis facility type dashboard
• Fig. 29 U.S. radiodermatitis market: Facility type movement analysis
• Fig. 30 U.S. Radiodermatitis distribution channel dashboard
• Fig. 31 U.S. radiodermatitis market: Distribution channel movement analysis
• Fig. 32 Key company categorization
• Fig. 33 Company market position analysis
• Fig. 34 Strategic framework

U.S. Radiodermatitis Market Growth & Trends:

The U.S. radiodermatitis market size is expected to reach USD 481.07 million by 2030, growing at a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several key factors, including the increasing prevalence of cancer, advancements in radiation therapy techniques, and the development of new treatment options for radiodermatitis are contributing to this growth. The growing burden of cancer is a significant factor driving market growth. With cancer being one of the leading causes of death worldwide, the demand for effective radiation therapy and subsequent management of radiodermatitis is growing. The high incidence of cancer types, such as breast and prostate cancers, which often require radiation therapy, is expected to boost market expansion. Moreover, the growing geriatric population, which is more susceptible to chronic diseases such as cancer, is boosting the demand for radiodermatitis treatment.

The market growth is also affected by the development of new treatment options for radiodermatitis, such as topical creams, dressings, and oral medications, which has expanded the market scope. Although these innovations offer patients more choices in managing their symptoms and potentially lead to improved quality of life & reduced healthcare costs associated with severe cases of radiodermatitis, they may also reduce the demand for traditional radiodermatitis management solutions. For instance, in April 2024, Molnlycke announced an agreement to acquire P.G.F. Industry Solutions GmbH, a prominent wound cleansing manufacturer. This acquisition is expected to help the company strengthen its position as a global leader in wound care.

Moreover, growth is also influenced by the increasing awareness and education among healthcare professionals & patients regarding the importance of managing radiodermatitis. This awareness has led to a greater emphasis on preventive measures and early intervention, which are crucial in minimizing the severity of radiodermatitis & improving patient outcomes. Collaborations between healthcare providers, researchers, and pharmaceutical companies to develop & promote effective radiodermatitis treatments further drive market expansion. Thus, the combined impact of the increasing prevalence of cancer, advancements in radiation therapy & treatment options, and the growing awareness & education about radiodermatitis management is expected to contribute to industry growth.

U.S. Radiodermatitis Market Report Highlights:

• The topical product segment accounted for a revenue share of 75.68% in 2023. This share can be attributed to the widespread use of topical products in managing the symptoms of radiodermatitis.
• Topical treatments, including creams & ointments, can be directly applied to the affected area, providing immediate relief and reducing the risk of systemic adverse effects.
• The retail pharmacies segment held the largest revenue share in 2023. This growth can be attributed to their accessibility and convenience. Retail pharmacies serve as a primary point of contact for many patients seeking over-the-counter treatments for conditions such as radiodermatitis.
• The independent radiotherapy centers segment held the largest revenue share in 2023. This is due to their focus on advanced radiotherapy treatments, reduced radiation exposure, and increased precision in tumor targeting. Moreover, these centers often have a more personalized approach, which can lead to higher patient satisfaction and repeat business.
• Market players are undertaking various strategic initiatives to enhance product reach and availability across different geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution channel
  • 1.2.3. Facility type
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. Epidemiology-based Market Analysis
  • 1.8.1. Research Scope and Assumptions
  • 1.8.2. Research Methodology and Assumptions
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Distribution channel
  • 2.2.3. Facility type
• 2.3. Competitive Insights

Chapter 3. U.S. Radiodermatitis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Related/ancillary market outlook
• 3.2. Prevalence of Different Cancer Types in the U.S.
• 3.3. Incidence and Mortality Rates of Different Cancer Types in the U.S. in 2024
• 3.4. Expected Cancer Incidence in the U.S. for 2024 (by States)
• 3.5. Number of Patients Opting for Radiation Therapy and Suffering From Radiodermatitis in the U.S. in 2024
• 3.6. Grades of Radiodermatitis for Different Cancer Types
• 3.7. Characterization of Radiodermatitis for Cancer Using Clinical Parameters
• 3.8. Facility Types for Radiation Therapy (for Different Types of Cancer in the U.S.)
• 3.9. Average Product Cost for Radiodermatitis Treatment
• 3.10. Product Market Opportunities
• 3.11. Market Dynamics
  • 3.11.1. Market driver Analysis
    • 3.11.1.1. Increasing cancer incidence
    • 3.11.1.2. Advancements in radiation therapy
  • 3.11.2. Market restraint analysis
    • 3.11.2.1. High cost of treatment
• 3.12. U.S. Radiodermatitis Market Analysis Tools
  • 3.12.1. Industry Analysis - Porter's
    • 3.12.1.1. Supplier power
    • 3.12.1.2. Buyer power
    • 3.12.1.3. Substitution threat
    • 3.12.1.4. Threat of new entrant
    • 3.12.1.5. Competitive rivalry
  • 3.12.2. PESTEL Analysis
    • 3.12.2.1. Political landscape
    • 3.12.2.2. Technological landscape
    • 3.12.2.3. Economic landscape

Chapter 4. U.S. Radiodermatitis Market: Product Estimates & Trend Analysis

• 4.1. U.S. Radiodermatitis Market: Product Dashboard
• 4.2. U.S. Radiodermatitis Market: Product Movement Analysis
• 4.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Topical
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.1. Corticosteroids
    • 4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Hydrophilic Creams
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Antibiotics
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Others
    • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Dressings
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.1. Hydrogel and Hydrocolloid Dressings
    • 4.5.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.2. No Sting Barrier Films
    • 4.5.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.3. Honey-Impregnated Gauze
    • 4.5.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.4. Silicone-Coated Dressings
    • 4.5.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.5. Others
    • 4.5.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

• 5.1. U.S. Radiodermatitis Market: Distribution Channel Dashboard
• 5.2. U.S. Radiodermatitis Market: Distribution Channel Movement Analysis
• 5.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Radiodermatitis Market: Facility Type Estimates & Trend Analysis

• 6.1. U.S. Radiodermatitis Market: Facility Type Dashboard
• 6.2. U.S. Radiodermatitis Market: Facility Type Movement Analysis
• 6.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Facility Type, 2018 to 2030 (USD Million)
• 6.4. Hospital-based Radiotherapy Centers
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Independent Radiotherapy Centers
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Stratpharma AG
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Type benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Smith & Nephew plc
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Type benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Molnlycke Health Care AB
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Type benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Derma Sciences Inc
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Type benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Convatec Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Type benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. 3M Company
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Type benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Alliqua BioMedical
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Type benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. BMG Pharma spA
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Type benchmarking
    • 7.3.9.4. Strategic initiatives